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Summary: In the development of cytotoxic T lymphocyte (CTL)-mediated
immunotherapy, the identification of CTL epitopes is of crucial importance.
Binding of a peptide to major histocompatibility complex (MHC) class I mol-
ecules is one of the prerequisites for its function as a CTL epitope. We describe
the technique, validation, and application of a simple cellular assay, intended
for the screening of peptides for binding, that can be applied to any human
leukocyte antigen (HLA) allele. Reconstitution of peptides in MHC class I
molecules after elution by acid treatment was previously shown to be possible
in specially engineered cell lines expressing only one type of MHC class 1, and
was applied for the HLA-A*0201 aliele. We now report the optimal conditions
for application of this type of binding assay to the HLA-A*030I allele. The
adaptations that were necessary to make the technique operational for HLA-
A*030l are shown in detail. These consisted of lowering the pH during acid
treatment to 2.9 and lengthening the duration of elution to 90 s. Furthermore,
immediate aspiration of eluted peptides appeared to be essential for this allele.
We found also that the use of Epstein-Barr virus (EBV)-transformed B cell
lines (B-LCL) yields results similar to those of the use of cell lines expressing
only one specific MHC class 1 allele. Homozygosity for the desired HLA allele
improves the sensitivity of the assay, but heterozygous cells can also be em-
ployed. Finally, we applied this technique to a search for HLA-A*030I binding
peptides derived from carcinoembryonic antigen (CEA). Of a set of 34 CEA-
specific peptides that fit with a specified HLA-A*0301-binding motif, we iden-
tified a set of six peptides with high binding affinity to this allele. These pep-
tides can be regarded as potential CTL epitopes. Key Words: HLA-A*030l—
CEA—Peptide binding—Elution—Binding affinity.
It is now generally agreed that only peptides with
a high binding affinity to a certain MHC class I
molecule can, potentially, function as a cytotoxic T
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lymphocyte (CTL) epitope (1-3). Both cellular and
molecular binding assays have been developed to
determine binding affinity of peptides to MHC class
I molecules (4-11), each with its specific advantages
and disadvantages, as reviewed subsequently. The
peptide-reconstruction assay, as presented in this
article, is the result of an effort to develop a simple




The T2-binding assay, a simple cellular assay that
measures upregulation of MHC class I on a peptide
processing-defective cell line after overnight incu-
bation with exogenous peptide, has been used suc-
cessfully to detect peptides binding to human leu-
kocyte antigen (HLA)-A*0201 (8,12,13). However,
its use is limited to this allele, as it depends on the
use of the processing-defective 174 CEM.T2 cell
line. Although the HLA-A*0201 allele is one of the
most frequently expressed class I alleles among the
different ethnic populations (14), only inclusion of
various other alleles will allow the development of
CTL-mediated immunotherapy for the significant
fraction of the population that does not express
HLA-A*0201. Other assays are required that may
be adopted for various HLA alleles to test peptide
binding.
Recently a cellular binding assay was described
(9) in which peptides presented in the MHC class I
of C1R cell lines (immortalized B-cell lines modified
to express only one HLA allele) were eluted ac-
cording to a method first described by Sugawara et
al. (15). Reconstitution of HLA-A*0201 was studied
by staining with a monoclonal antibody against
MHC class I, W6/32. This assay is simple to per-
form, and the principle can be applied to any HLA
allele. However, its application is limited to those
alleles of which a C1R transfectant is available. ,
A molecular binding assay has been described
(11) in which peptides that are tested for binding to
the purified class I molecules compete for this bind-
ing with specific radiolabeled standard peptides. As
with other molecular binding assays (7), the princi-
ple can be employed for any class I molecule, but
the assays involve the use of radioactive iodine and
purified MHC class I molecules.
We developed a technique to use B-LCL lines for
a cellular binding assay based on the same principle
as previously described in the so-called peptide-
reconstitution assay (9), because B-LCL lines ex-
pressing any desired HLA phenotype can be ob-
tained rather easily by Epstein-Barr virus (EBV)
transformation of peripheral blood lymphocytes of
a blood donor expressing the desired phenotype.
Under acid conditions, peptide is eluted from the
MHC class I molecules, resulting in denaturation of
the trimolecular complex consisting of HLA, pep-
tide, and p-2 microglobulin (p2M). In the presence
of p2M, exogenous peptide with adequate binding
affinity will bind to empty MHC class 1 at the cell
surface, thus reconstituting the trimolecular com-
plex, and only such a configuration is recognized by
monoclonal antibodies like BB 7.2 (for HLA-A2)
and GAP A3 (for HLA-A3).
We compared the use of B-LCL lines, both ho-
mozygous and heterozygous for HLA-A*0201 and
HLA-A*0301. For HLA-A*0301 we also compared
these B-LCLs with the C1R A3 cell line.
Once optimal conditions had been established for
the peptide-reconstitution assay in HLA-A*0201
and HLA-A*0301, results from our assay were
compared with those obtained with identical pep-
tides in other assays.
Carcinoembryonic antigen (CEA) is a physiologic
glycoprotein that is grossly overexpressed in most
colorectal cancers and many other carcinomas (16-
18) because of a failure of excretion in malignant
cells (19,20). This overexpression appears to be lim-
ited to carcinoma in adult humans (21). Because
CEA might therefore be a very attractive target for
CTL-mediated immunotherapy, we applied the
technique for identification of CEA-derived pep-
tides with high-affinity binding to HLA-A*0301.
MATERIALS AND METHODS
Cell Lines
The B-LCL lines used in the experiments were
JY, an HLA-A*0201 homozygous cell line; EKR,
an HLA-A*0301 homozygous cell line; and D-O, a
heterozygous cell line expressing both HLA-
A*0201 and HLA-A*0301. We used the C1R A3 cell
line, an HLA-A and HLA-B knockout B-cell line
transfected with HLA-A*0301. Furthermore, we
used the human processing-defective cell line 174
CEM.T2 (T2) (22). (Both the C1R A3 and T2 cell
lines were kindly provided by P. Creswell, Depart-
ment of Immunology, Yale University, New Ha-
ven, CT, U.S.A.)
Cells were cultured at 37°C, 5% CO2, and RPMI
1640 Dutch modification (Gibco, Life Technologies,
Paisley, Scotland), supplemented with 2 mM glu-
tamine (referred to as RPMI medium), 10% fetal
calf serum (PCS) and 5 x 10~5 M 2-mercaptoetha-
nol (for the B-LCL lines) or Iscove's modification
of Dulbecco's medium (IMDM; Gibco) supple-
mented with 10% ECS and 2 mM glutamine (for the
C1R A3 and T2 cell lines). Cells were always sup-
plied with fresh culture medium the day before an
experiment, and adjusted to between 0.5 x !06 and
l x 106 cells/ml.
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Antibodies
The sources of the anti-HLA-A2 and -HLA-A3
antibodies were hybridoma culture supernatant of
BB 7.2 (HB82-ATCC) and GAP A3 (HB 122-ATCC)
[American Tissue Type Collection (ATCC), Rock-
vine, MD, U.S.A.], respectively (23,24). To con-
firm allele specificity, al! cell lines used in the ex-
periments were stained with both antibodies and a
second-antibody-only negative control (GaM
FITC).
Peptides
For control purposes, we used peptides with
known HLA-A*0201 and HLA-A*0301 binding pa-
rameters, as shown in Table 1.
Our group previously described binding motif-
guided computerized selection of peptides poten-
tially binding to HLA-A*0201 (8,25). We used this
computer scoring system and thus selected all
CEA-specific peptides, eight to 11 amino acids
long, that fit with the following binding motif for
HLA-A*0301, based on the observations of Kubo et
al. (26), and a comprehensive list of peptides natu-
rally occurring in HLA-A*0301 (27,28): all peptides
had L/l/V/M (one-letter amino acid code) at posi-
tion 2 from the N-terminus, and K/R/Y at the C-ter-
minus. These 34 peptides were synthesized and dis-
solved as described (8), adjusted to a pH between
6.5 and 7.5, aliquoted, and stored at -20°C.
Peptide-Reconstitution Assay
The peptide-reconstitution assay is a three-step
procedure, consisting of elution (step 1), reconsti-
tution of the trirnolecular complex associated with a
specific monoclonal antibody (step* 2), and counter-
staining with a fluorescent second antibody and fix-
ation for flowcytometric analysis (step 3).
Step 1. 7 million cells were washed twice in 5(f rnl
of phosphate-buffered saline (PBS). Supernatant
was aspirated, the pellet resuspended in the residual
PBS, and rested on ice for 10 min. Cells an ice were
eluted by carefully rinsing with 3 ml of citrate phos-
phate buffer [0.131 M citric acid and 0.066 M
Na,HPO4 (adjusted to the desired pH) for 90 s (un-
less stated otherwise)]. Then 47 ml of IMDM (0°C)
without supplements was added, and cells were
spun down immediately at 2,000 r/min (690 g) for 3
min, washed again in IMDM, and resuspended in
1.5 ml of RPMI medium.
Step 2. Wells of a 96-well U-bottom cell-culture
plate (Costar, Cambridge, MA, U.S.A.) were filled
with a saturating amount of 110 1̂ of first antibody,
supplemented with fJ2M (final concentration of 1
M,g/ml). Subsequently 25 nl of peptide solution di-
luted in RPMI medium (maximum final concentra-
tion, 400 |Ag/ml) and, finally, 15 pil of the cell sus-
pension was added to each well (final volume, 150
|J).
Step 3. After 4-h incubation at room temperature,
the cells were spun down at 1,300 r/min for 5 min,
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washed twice in 100 \t\ of PBS/BSA 1%, and incu-
bated with 50 u,l of FITC-conjugated goat anti-
mouse immunoglobulin (OaM FITC, Boehringer
Mannheim, Germany), dissolved 1:100 in PBS/BSA
1% per well at 4°C for 30 min. Cells were washed
again, and finally cells were resuspended in 100 n.1
of 0.5% paraformaldehyde in PBS. Cells were ana-
lyzed using a Becton-Dickinson FACScan flowcy-
tometer, and the mean fluorescence (mF) was de-
termined.
The following values were calculated: fluores-
cence index (FI) was defined as the increase of
mean fluorescence in the sample (eluted cells incu-
bated with the peptide) over the background as a
fraction of that background (background = eluted
cells incubated with 25 jj.1 of RPMI instead of pep-
tide):
Fl = (mF (sample) - mF (background)) /
mF (background) (1)
An FTX0.5 was considered to indicate no signifi-
cant binding affinity of the peptide for the allele
concerned.
It is known from our experience with the T2 as-
say that serial dilution of the peptide results in an
S-shaped curve when FI is plotted against peptide
concentration on a logarithmic peptide concentra-
tion x axis. The level of the plateau (maximum F!)
is correlated with the binding affinity of the peptide
in the T2 assay (8,i2),
The concentration at which half of the maximum
FI is reached (the '/imax value) is inversely corre-
lated with binding affinity in the T2 assay (13). The
'/2max was determined by plotting the Fl against the
concentration of peptide. A Vimax in the same
range as the values established for known CTL
epitopes was considered indicative of high binding
affinity.
RESULTS
Effect of pH and Length of Blution
Mild acid treatment of B-LCL for 60 s at pH 3.3
wa£ reported sufficient for elution of HLA-A*0201
mokcules (9). The same treatment applied even for
90 s resulted in a very moderate decrease of 35%
(mF from 320 to 210) of cell surface HLA-A*0301
(Fig. 1), indicating a relatively low MHC class I
dissociating effect of the treatment in both B-LCL
and C1R A3.
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FIG. 1. Elution of HLA-A*0201 and HLA-A*0301 on the het-
erozygous B-LCL line D-O, measured as reduction of mean flu-
orescence al various pH values. Reequilibration in medium took
place after 90 s.
resulted in a progressive dissociation of the MHC
class I complex. HLA-A*0201 complex dissociation
occurred at a pH <5, reaching a plateau at pH 3.5.
Dissociation of HLA-A*0301 required a pH <3.5,
and at pH 2.9, only a hint of a plateau was seen (Fig,
1). However, down to a pH of 2.9, -85% of cells
survived acid treatment, whereas further lowering
of the pH resulted in a sudden and sharp decrease in
cell survival to 68% at pH 2.75, as determined by
trypan blue exclusion (data not shown).
Increasing the duration of acid treatment at a
given pH also resulted in progressive dissociation.
However, maximum effect was reached after 30 s in
HLA-A*0201, whereas 90 s was required for HLA-
A*0301 (Fig. 2).
Under conditions of optimal elution for each al-
lele, an mF level was reached of ~10% of the ïeve!
found with cells that had not been eluted (pH 7.4 in
Fig. 1). Dissociation of the HLA-A*0301 complex
required more vigorous acid treatment, both in pH
and duration, possibly indicating stronger binding
forces within the trimolecular complex of HLA-
A*0301.
The allele specificity of the antibodies used in
these experiments was confirmed by staining all cell
lines used with both antibodies and a second-
antibody-only negative control (GaM FITC), as
shown in Fig. 3.
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FIG. 2. Elution of HLA-A*0201 at pH 3.2 and HLA-A*030l at
pH 2.9 on the heterozygous fl-LCL line D-O, measured as re-
duction of mean fluorescence as a function of duration of acid
treatment after which reequilibration in medium look place.
Influence of Horaozygous Versus Heterozygous HLA
Allele Expression on FI and Vimax Values
The differences in HLA-A*020I and HLA-
A*030I expression encountered when various cell
lines were tested (Fig. 3) urged us to investigate the
effect of these differences on the results of the pep-
tide-reconstitution assay. This was done by testing
B-LCL lines of both homozygous (JY, EKR) and
heterozygous (D-O) HLA phenotypes when incu-
bated with peptides of high or low binding affinity.
To study HLA-A*0201 peptide elation, we used hu-
man immunodeficiency virus (HIV) pol 468-476
[ILKEPVHGV, an HLA-A*0201 restricted CTL
epitope (29)], and CEA 308-318 [ALTCEPEIQNT,
a peptide that never showed significant upregula-
tion of HLA-A*0201 in the T2 assay (our observa-
tions)]. To study HLA-A*0301 peptide elution, we
used HIV nef 73-82 [QVPLRPMTYK, an HLA-
A*0301 restricted CTL epitope (30)], HIV pol 468-
476 [one primary anchor and three amino acids on
positions in which they are abundantly present in
peptides eluted from HLA-A*0301 molecules (26)].
As a negative control peptide, we used CEA 353-
361 (DVGPYECG1, a peptide that never showed
any sign of binding to HLA-A*0201 or HLA-
A*0301, either in T2 or in our peptide-reconstitution
assays).
For all peptides, the FI curves were of identical
shape, irrespective of the cell line used (homozy-
gous, heterozygous, or C1R variant for the desired
HLA alleie) (Figs. 4 and 5). However, Vimax values
for HIV pol 468-476 and CEA 308-318 were 2 and 20
M-g/ml, respectively, when we used the homozygous
ceil line, and 5 and 55 u,g/ml when the heterozygous
cell line was employed. For HIV nef 73-82 and HIV
pol 468-476, the respective values were 3 and 25
u,g/ml and 5 and 40 jig/ml, and by using the CIR A3
cell line, the respective Vimax values were 2 and 20
(jLg/ml (Figs. 4 and 5). ',
This indicates that the assay may be carried out
with cells with either homozygous or heterozygous
expression of the HLA alleie tested, but^sensitivity
for binding at low peptide concentrations is higher
in homozygous cell lines.
Validation of the Assay
The use of peptides with known binding affinity
to HLA-A*0201 and HLA-A*0301 enabled us to
validate our assay in its ability to quantify binding
affinity of peptides. For HLA-A*0201, we tested
p53 and CEA peptides, using the HLA-A*0201 ho-
mozygous JY cell line, and determined their maxi-
mum F! and Vzmax values, to compare these with
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FIG. 3. Specificity with monoclonal antibodies against HLA-
A2 (BB 7.2), HLA-A3 (GAP A3), and FITC-conjugated goat
anti-mouse immunoglobulin (GaM FITC) only, and differences
in expression of the respective HLA alleles. demonstrated on the
processing-defective cell line T2, the CIR A3 cell line, express-
ing only HLA-A"030I, JY (B-LCL, homozygous for HLA-
A*0201), EKR (B-LCL homozygous for HLA-A*0301), and D-O
(B-LCL, HLA-A*0301, and HLA-A«0201).
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FIG. 4. Reconstitution with peptides of high (HtV pol 468-476, ILKEPVHGV), intermediate (CEA 308-318, ALTCEPEIQNT), and
very low (CEA 353-361, DVGPYECGl) binding affinity to HLA-A*020I on JY (homozygous for the allele) and D-0 (heterozygous,
HLA-A'0201 and HLA-A*0301) B-LCL.
tions). ViMax values in both tests did not differ sig-
nificantly (Table 2).
For HLA-A*0301, we tested seven peptides de-
rived from HPV 16 E6 and E7, of which the binding
affinities to HLA-A*0301 were previously pub-
lished-^ 1; Table 2 ranked to the published 1C50 val-
ues, the peptide concentration resulting in 50%
binding inhibition of the reference peptide). The
peptides with the lowest IC50 (HPV 16 E6 125-133
and HPV 16 E 6 7-15) had '/imax values at the low
end of the range we found (5 and 6 u.g/ml, respec-
tively). The peptides with the highest IC50 (HPV 16
E 6 143-151 and HPV 16 E6 42-50) were at the high
end of the range encountered (35 and 55 jig/ml, re-
spectively).
Thus the results in these different assays led to a
similar hierarchy of binding affinity.
Binding Affinity for HLA-A*0301 of Selected
CEA Peptides
The selected 34 CEA specific peptides complying
with the HLA-A*0301 peptide-binding motif de-
scribed were tested in peptide-reconstitution assay
in serial dilution on the HLA-A*0301 homozygous
EKR cell line (Table 3). Eight peptides did not show
any significant binding affinity, illustrated by an
'/2max 3=400 u,g/m! (Table 3) in combination with a
very low FI (*0.5, data not shown). Half max val-
ues of 19 peptides were in the same range as the
HPV-derived binding peptides tested (Wmax ^55
M-g/ml), six of which were in the same range C/zmax
=£16 u,g/ml) as the three best binding HPV-derived
peptides tested (1C50) (Tables 2 and 3).
This indicates that six CEA-specific peptides
FIG. 5. Reconstitution with peptides of
high (HIV nef 73-81, QVPLRPMTYK), in-
termediate (HIV pol 468-476, IL-
KEPVHGVK.and very low (CEA 353-361,
DVGPYECGl) binding affinity to HLA-
A"0301 on EKR (B-LCL homozygous for
the allele), D-O (B-LCL, heterozygous,
HIsA-A*020l and HLA-A*0301), and C1R
A3 tHLA-A'0301 only) cell lines.
p*pt!d* eoncvntiatlon
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Peptide Reference assay assay
HLA-A*0201 T2 assay
yanax. (ng/mi) I'jmax (|ig/ml)
p53 25-35 6 5
HIV pol 468-476 8 2
p53 187-197 8 25
p53 65-73 12 10
p53 264-272 26 8
CEA 353-361 >100 >400
HLA-A*0301 Molecular binding assay
1C,,, (nM) Wmax (|ig/mt)
E6 125-133 68 5
E6 7-15 290 6
E6 93-101 384 16
E6 89-97 1,111 5
E6 75-83 3,000 12
E6 143-151 4,285 35
E6 42-50 5,000 55
Human p53-, CEA-, and HIV-derived HLA-A*0201 binding
peptides tested in the T2 assay and the peptide-reconstitution
assay. Stated are the position of the peptide and f/zmax values for
both assays. HPV 16-derived peptides were tested in the pep-
tide-reconstitution assay and the molecular-binding assay.
Stated are the 50% inhibition by competition (IC50) values in the
molecular-binding assay (Kast et al., 1994) and the Vimax values
in the peptide-reconstitution assay for binding to HLA-A*0301.
HLA, human leukocyte antigen; CEA, carcinoembryonic an-
tigen; HIV. human immunodeficiency virus; HPV, human pap-
Uloma virus.
have such binding affinity that they can be desig-
nated as being potential HLA-A*0301-restricted
CTL epitopes.
DISCUSSION
In the search for MHC class I binding peptides as
targets for CTL-mediated immunotherapy, the po-
tential effectiveness of which has been demon-
strated in both murine models (31-33) and made
likely in humans (34,35), there is a need to identify
potential CTL epitopes binding to a great variety of
HLA alleles to cover a majority of the population.
B-LCL with any HLA expression can be ob-
tained rather easily. Therefore, we adapted the pep-
tide-reconstitution assay as originally described (9)
for use with such B-LCL lines and established the
practical application of this assay for the HLA-
A*0301 allele. Of course, having established the op-
timal circumstances for elution of this molecule, the
technique might also be used to prepare antigen-
presenting cells for primary CTL response induc-
tion.
The peptide reconstitution assay combines a
number of advantages of the T2-btnding assay with
the advantages of molecular binding assays. The
assay does not involve radioactive components,
and apart from a flow cytometer, no specialized
equipment in the laboratory is required. Because
B-LCL can be- applied, it is possible to study pep-
tide-binding affinities for any HLA allele, provided
an allele-specific antibody is available. •.
Whether peptide binding to isolated MHC class' 1
molecules differs from binding to the MHC class I
in its native biological context, the intact, cell (-sur-
face), has not been established yet. If such differ-
ences do occur, it seems likely that a cellular btnd-
TABLE Ï. Reconstitution of HLA-A*0301 with
exogenous CEA-derived peptides after elution at pH 2.9
'AMax




































'/iMax values of carcinoembryonic antigen (CEA)-derived
peptides for binding to HLA-A*0301 in the peptide-
reconstitution assay in micrograms per milliliter. Stated are the
amino acid sequence in one letter code, and the position of the
first amino acid from the N-terminus of the protein.
HLA, human leukocyte antigen; CEA, carcinoembryonic an-
tigen.
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ing assay gives more realistic information about
potential immunogenicity of the peptide when pre-
sented by the MHC class 1 molecule to the CTL.
To take advantage of the possibilities of the pep-
tide-reconstitution assay, we adapted the assay for
use on another HLA allele than the HLA-A*0201
described originally. Applying this strategy, in prin-
ciple, all types of HLA alleles can be tested for
peptide binding. Considerable differences in acid
treatment conditions required for elution of HLA-
A*0201 and HLA-A*0301 were encountered. These
differences were allele specific and not cell-line de-
pendent. The required acid treatment conditions for
either of the alleles tested were identical in any of
the cell lines tested, whether homozygous B-LCL,
heterozygous B-LCL, or C1R variant.
Further investigation is needed to establish
whether the differences in acid treatment conditions
required for optimal elution of peptide from the re-
spective MHC class I molecules is reflected in dif-
ferenees in immunogenicity of peptides presented
by these alleles. Such a relation is not unlikely, be-
cause so far, peptide-binding affinity is closely re-
lated to immunogenicity (2).
When identical peptides were tested on different
cell lines in the peptide reconstitution assay, FI
curves for each peptide were identical in shape
(Figs. 4 and 5), resulting in a comparable discrimi-
nation between strong, weak, and nonbinding pep-
tides, irrespective of the use of homozygous, het-
erozygous, or the C1R A3 cell line.
When the homozygous and C1R A3 cell lines
were used, the range of Vimax values was wider and,
therefore, supposedly more accurate differentiation
between binding affinities of the peptides tested is
possible. '/sMax values were ~2 to 3 times lower,
indicating a higher sensitivity for binding at low
peptide concentrations when homozygous cells are
used.
To validate the assay, p53-derived HLA-A*0201-
binding peptides were tested in the peptide-re-
constitution assay. Compared with the results from
the T2 assa"y, the outcome of testing HLA-A*0201-
binding p53 peptides in the peptide-reconstitution
assay was mainly similar. Comparison of the HPV-
denived peptides with different binding affinity
known from the molecular binding assay (1) shows
good correlation with the 'Amax values established
using the peptide-reconstitution assay. One peptide
(p53 264-272) appeared to have relatively lower
binding affinity in the T2 assay than in the peptide-
reconstitution assay. A similar phenomenon was
noted for HLA-A*0301 when the 1C50 values of the
HPV-derived peptides in the molecular-binding as-
say were compared with the findings in the peptide-
reconstitution assay. Similar discrepancies in rank-
ing of binding affinity were found before when p53
peptide binding was studied in the T2 binding and
T2 competition assay (13).
Such discrepancies might be caused by the con-
siderable differences in incubation time between the
peptide-reconstitution assay and the other test:
whereas association rate and dissociation rate to-
gether cause an equilibrium (molecular binding) or
stable effect (T2) reached during overnight incuba-
tion, a high association rate could cause features of
high binding affinity in the peptide-reconstitution
assay. The presence of the native biological context
might also contribute to such discrepancies.
The peptide-reconstitution assay is a valid and
useful instrument in determining peptide-binding af-
finity to MHC class I; by the application of B-LCL,
any phenotype can be studied, provided an allele-
specific antibody is available. We demonstrated
here that the used cells are preferably homozygous
for the HLA allele studied, because this results in
higher sensitivity, especially at low peptide concen-
trations; however, in the unlikely event that a ho-
mozygous B-LCL cannot be made avaüable, a het-
erozygous cell line may be used. Therefore, it may
be a very useful tool in the development of CTL-
mediated immunotherapy.
We applied the peptide-reconstitution assay using
a B-LCL line homozygous for HLA-A*0301 to test
binding affinity of 34 binding-motif-selected CEA-
specific peptides. Six of these had binding affinities
in the same range as high-affinity binding peptides
of viral origin and can therefore be designated to be
potential CTL epitopes.
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